Nodosin
Based on 1 Customer Validation
Nodosin is an orally active diterpenoid compound that can be isolated from Isodon serra. Nodosin can inhibit the proliferation and induce cell cycle arrest and apoptosis of tumor cells. Nodosin can also inhibit oxidative stress, inflammatory responses, and ferroptosis. Nodosin has anti-inflammatory and anti-tumor activities.
For research use only. We do not sell to patients.
- Purity : 98.61%
- CAS No.: 10391-09-0
- Formula: C20H26O6
- Molecular Weight:362.42
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 16
|
Cytotoxicity against human A549 cells after 48 hrs
Cytotoxicity against human A549 cells after 48 hrs
|
[PMID: 19697926] |
| A549 | IC50 |
>40 μM
Compound: 9
|
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| HepG2 | IC50 |
1.92 μM
Compound: 16
|
Cytotoxicity against human HepG2 cells after 48 hrs
Cytotoxicity against human HepG2 cells after 48 hrs
|
[PMID: 19697926] |
| HL-60 | IC50 |
15 μM
Compound: 9
|
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| K562 | IC50 |
0.54 μM
Compound: 16
|
Cytotoxicity against human K562 cells after 48 hrs
Cytotoxicity against human K562 cells after 48 hrs
|
[PMID: 19697926] |
| MCF7 | IC50 |
23.5 μM
Compound: 9
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| RAW264.7 | IC50 |
18.4 μM
Compound: 9
|
Inhibition of LPS-stimulated NO production in mouse RAW264.7 cells after 18 hrs by Griess assay
Inhibition of LPS-stimulated NO production in mouse RAW264.7 cells after 18 hrs by Griess assay
|
[PMID: 24219809] |
| SMMC-7721 | IC50 |
27 μM
Compound: 9
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| SW480 | IC50 |
12.1 μM
Compound: 9
|
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| SW780 | IC50 |
9.99 μM
Compound: Nodosin
|
Cytotoxicity against human SW780 cells assessed as reduction in cell growth by CCK8 assay
Cytotoxicity against human SW780 cells assessed as reduction in cell growth by CCK8 assay
|
[PMID: 35976233] |
| T-24 | IC50 |
4.91 μM
Compound: Nodosin
|
Cytotoxicity against human T24 cells assessed as reduction in cell growth by CCK8 assay
Cytotoxicity against human T24 cells assessed as reduction in cell growth by CCK8 assay
|
[PMID: 35976233] |
| UMUC3 | IC50 |
3.45 μM
Compound: Nodosin
|
Cytotoxicity against human UMUC3 cells assessed as reduction in cell growth by CCK8 assay
Cytotoxicity against human UMUC3 cells assessed as reduction in cell growth by CCK8 assay
|
[PMID: 35976233] |
In Vitro
Nodosin (0-30 μM; 18-72 h) can inhibit the growth of multiple tumor cell lines (the IC50 values for SNU638, SK-HEP-1, A549, HCT116, and MDA-MB-231 are 7.53, 5.33, 13.73, 4.05, and 7.12 μM, respectively), and induce cell cycle arrest and apoptosis in HCT116 cells. The mechanism involves the inhibition of the Wnt/β-catenin signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cells
-
Concentration:0, 7.5, 15 and 30 μM
-
Incubation Time:18 h
-
Result:Significantly suppressed Wnt/β-catenin target protein expressions including β-catenin, p-GSK-3β, c-Myc, and Survivin.
In Vivo
Nodosin (100 μg/mL; tail vein injection; single dose) has a protective effect in a rat liver transplantation model. It can reduce the pathological damage of rat liver tissue, decrease the number of apoptotic hepatocytes, and promote hepatocyte proliferation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (180±20 g, 8 weeks old) treated LPS (HY-D1056) to establish the acute kidney injury model[2]
-
Dosage:2 and 4 mg/kg
-
Administration:Oral administration; 7 days
-
Result:Significantly decreased Serum Scr, BUN, urine NGAL, and KIM-1 levels.
Decreased the levels of kidney MDA and 4-HNE, increased the levels of antioxidant enzymes (SOD, CAT, GPx, GST) and Nrf2, NQO1, HO-1, and reduced Keap-1 mRNA levels.
Reversed excessive ferroptosis in the kidneys, as indicated by increased mRNA and protein levels of GPX4, SLC7A11, and FTH-1.
Significantly reduced the levels of inflammatory markers (TLR4, MYD88, NF-κB p65, IKKβ, IL-1β) and increased IL-10 levels.
Seduced Histopathological changes in the kidneys.
Chemical Information
-
CAS No. 10391-09-0
-
Appearance Solid
-
Molecular Weight 362.42
-
Formula C20H26O6
-
Color White to off-white
-
SMILES
O[C@H]1[C@@]([C@]2(C(C3=C)=O)C[C@H]3C1)([H])[C@@]([C@@](CC4)([H])OC2=O)(CO5)[C@](C4(C)C)([H])[C@@H]5O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (344.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bae ES, et al. Anti-Proliferative Activity of Nodosin, a Diterpenoid from Isodon serra, via Regulation of Wnt/β-Catenin Signaling Pathways in Human Colon Cancer Cells. Biomol Ther (Seoul). 2020 Sep 1;28(5):465-472. [Content Brief]
[2]. Su C, et al. Protective effects of nodosin against lipopolysaccharide-induced acute kidney injury through regulation of oxidative stress, inflammation, and ferroptosis in rats. Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):8009-8022 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7592 mL | 13.7961 mL | 27.5923 mL | 68.9807 mL |
| 5 mM | 0.5518 mL | 2.7592 mL | 5.5185 mL | 13.7961 mL | |
| 10 mM | 0.2759 mL | 1.3796 mL | 2.7592 mL | 6.8981 mL | |
| 15 mM | 0.1839 mL | 0.9197 mL | 1.8395 mL | 4.5987 mL | |
| 20 mM | 0.1380 mL | 0.6898 mL | 1.3796 mL | 3.4490 mL | |
| 25 mM | 0.1104 mL | 0.5518 mL | 1.1037 mL | 2.7592 mL | |
| 30 mM | 0.0920 mL | 0.4599 mL | 0.9197 mL | 2.2994 mL | |
| 40 mM | 0.0690 mL | 0.3449 mL | 0.6898 mL | 1.7245 mL | |
| 50 mM | 0.0552 mL | 0.2759 mL | 0.5518 mL | 1.3796 mL | |
| 60 mM | 0.0460 mL | 0.2299 mL | 0.4599 mL | 1.1497 mL | |
| 80 mM | 0.0345 mL | 0.1725 mL | 0.3449 mL | 0.8623 mL | |
| 100 mM | 0.0276 mL | 0.1380 mL | 0.2759 mL | 0.6898 mL |